News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
MORRIS TIMOTHY E
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/17/2022 |
4
| MORRIS TIMOTHY E (Director) has filed a Form 4 on Aquestive Therapeutics, Inc.|
Txns:
| Granted 28,500 options to buy
@ $1.5, valued at
$42.8k
|
|
| 07/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/14/2022 |
4
| MORRIS TIMOTHY E (COO and CFO) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 59,841 options to buy
@ $2.99, valued at
$178.9k
|
|
| 01/04/2022 |
4
| MORRIS TIMOTHY E (COO and CFO) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 51,000 options to buy
@ $3.72, valued at
$189.7k
|
|
| 06/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/02/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 09/22/2020 |
4
| MORRIS TIMOTHY E (COO and CFO) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 151,316 options to buy
@ $9.65, valued at
$1.5M
|
|
| 03/06/2019 |
4
| MORRIS TIMOTHY E (CFO) has filed a Form 4 on IOVANCE BIOTHERAPEUTICS, INC.|
Txns:
| Granted 100,000 options to buy
@ $11.26, valued at
$1.1M
|
|
| 03/13/2018 |
4
| MORRIS TIMOTHY E (Director) has filed a Form 4 on HUMANIGEN, INC|
Txns:
| Granted 715,877 options to buy
@ $0.665, valued at
$476.1k
Granted 88,235 options to buy
@ $0.665, valued at
$58.7k
|
|
| 08/16/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/16/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/09/2017 |
4
| MORRIS TIMOTHY E (CFO) has filed a Form 4 on ACELRX PHARMACEUTICALS INC |
| 09/15/2016 |
4
| MORRIS TIMOTHY E (Director) has filed a Form 4 on KALOBIOS PHARMACEUTICALS INC |
| 07/11/2016 |
3
| MORRIS TIMOTHY E (Director) has filed a Form 3 on KALOBIOS PHARMACEUTICALS INC |
| 02/18/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 05/01/2015 |
4
| MORRIS TIMOTHY E (CFO) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Granted 100,000 options to buy
@ $4.24, valued at
$424k
|
|
| 12/04/2014 |
4
| MORRIS TIMOTHY E (CFO) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Granted 100,000 options to buy
@ $6.6, valued at
$660k
|
|
| 05/08/2014 |
4
| MORRIS TIMOTHY E (CFO) has filed a Form 4 on ACELRX PHARMACEUTICALS INC|
Txns:
| Granted 200,000 options to buy
@ $10.34, valued at
$2.1M
|
|
| 09/09/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/20/2012 |
4
| MORRIS TIMOTHY E (VP, Finance and CFO) has filed a Form 4 on VIVUS INC|
Txns:
| Sold 25,000 shares
@ $30.36, valued at
$759k
Exercised 25,000 options to buy
@ $4.23, valued at
$105.8k
|
|
| 02/27/2012 |
4
| MORRIS TIMOTHY E (SVP, Finance and CFO) has filed a Form 4 on VIVUS INC|
Txns:
| Sold 4,267 shares
@ $20.69, valued at
$88.3k
Sold 91 shares
@ $20.69, valued at
$1.9k
Sold 56,183 shares
@ $20.69, valued at
$1.2M
Sold 43,817 shares
@ $20.69, valued at
$906.6k
Sold 25,000 shares
@ $20.9, valued at
$522.5k
Sold 125,000 shares
@ $20.69, valued at
$2.6M
Sold 25,000 shares
@ $21.55, valued at
$538.8k
Sold 20,544 shares
@ $22.93, valued at
$471.1k
Sold 4,456 shares
@ $22.93, valued at
$102.2k
Sold 25,000 shares
@ $24.9, valued at
$622.5k
Exercised 91 options to buy
@ $4.15, valued at
$377.7 |
|
| 01/31/2012 |
4
| MORRIS TIMOTHY E (VP, Finance and CFO) has filed a Form 4 on VIVUS INC|
Txns:
| Granted 8,970 options to buy
@ $12.04, valued at
$108k
Granted 81,030 options to buy
@ $12.04, valued at
$975.6k
|
|
| 01/25/2011 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 06/16/2010 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 01/26/2010 |
4
| MORRIS TIMOTHY E (VP, Finance & CFO) has filed a Form 4 on VIVUS INC|
Txns:
| Granted 80,000 options to buy
@ $8.91, valued at
$712.8k
|
|
| 01/27/2009 |
4
| Form 4 -- Statement of changes in beneficial ownership of securities |
| 02/14/2003 |
5
| Form 5 -- Annual statement of changes in beneficial ownership of securities |
|
|